📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
5 analysed today
FollowTelegram
5
Today
151,865
All-time analysed
43,538
Positive
6,743
Negative
92,747
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
270 announcements match the current filters (relevance ≥ 5).
Strides Pharma Elevates COO to Executive Director; Promoter Transitions to Non-Executive Role
Strides Pharma Science Limited has announced a leadership reshuffle effective June 1, 2026, aimed at professionalizing management and strengthening its board. Current COO Venkata Seetharama Raju Pakalapati, who has been with the group for over 18 years, will be elevated to Executive Director for a three-year term. Aditya Arun Kumar, a member of the promoter group, will transition from his executive role to a Non-Executive Director position. Additionally, two Executive VPs have been nominated as Senior Management Personnel to bolster the company's leadership framework.
Key Highlights
COO Venkata Seetharama Raju Pakalapati promoted to Executive Director and KMP for a 3-year term starting June 1, 2026.
Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to further professionalize management.
Nandini Matiyani (HR) and Ariff Khan (Manufacturing) inducted as Senior Management Personnel (SMP).
The reshuffle is part of a comprehensive succession planning framework and internal talent promotion strategy.
👀 What to Watch
These changes reflect a move toward a more professionalized management structure and internal succession. Investors should monitor if this transition leads to improved operational efficiency in global technical operations.
Strides Pharma Elevates COO to Executive Director; Promoter Steps Back to Non-Executive Role
Strides Pharma Science Limited has announced a significant management reshuffle effective June 1, 2026, aimed at professionalizing its leadership. The current COO, Venkata Seetharama Raju Pakalapati, who has 18 years of experience with the company, has been elevated to the Board as an Executive Director for a three-year term. Simultaneously, Aditya Arun Kumar, a member of the promoter group, will transition from an executive role to a Non-Executive Director. These changes are part of a comprehensive succession planning framework and include the promotion of Nandini Matiyani to Group CHRO.
Key Highlights
Venkata Seetharama Raju Pakalapati (Ram) elevated to Executive Director and KMP effective June 1, 2026
Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to professionalize management
Nandini Matiyani promoted to Group CHRO and nominated as Senior Management Personnel (SMP)
Ariff Khan, EVP of Manufacturing Operations, also nominated as Senior Management Personnel
The changes follow a Board meeting held on May 18, 2026, based on NRC recommendations
👀 What to Watch
Investors should view the move to professionalize management and the elevation of a long-term internal leader as a positive governance signal. Monitor the company's operational efficiency under the new leadership structure starting June 2026.
Strides Pharma Reshuffles Board: COO Ramaraju PVS Promoted to Executive Director
Strides Pharma Science Limited has announced a strategic management reshuffle effective June 1, 2026, aimed at professionalizing its leadership and implementing a succession framework. Current COO Ramaraju PVS, who has been with the company for 18 years, is being elevated to the Board as an Executive Director for a three-year term. Simultaneously, Aditya Arun Kumar, a member of the promoter group, will transition from an executive role to a Non-Executive Director position. The company also appointed Nandini Matiyani as Group CHRO and Ariff Khan as Senior Management Personnel to strengthen its executive layer.
Key Highlights
Ramaraju PVS (COO) elevated to Executive Director and Key Managerial Personnel for a 3-year term starting June 1, 2026.
Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to further professionalize management.
Nandini Matiyani, with over 20 years of HR experience, redesignated as Group CHRO and Senior Management Personnel.
Ariff Khan, Executive VP of Manufacturing Operations, nominated as Senior Management Personnel.
The reshuffle follows a Board meeting held on May 18, 2026, and is subject to shareholder approval.
👀 What to Watch
Investors should view the promotion of an internal veteran to the board and the promoter's transition to a non-executive role as a positive step toward professional governance. No immediate action is required, but monitor the company's operational efficiency under the new leadership structure.
Strides Pharma Recommends ₹5 Final Dividend for FY26 Following Audited Results Approval
Strides Pharma Science Limited has recommended a final dividend of ₹5 per equity share (50% of face value) for the financial year ended March 31, 2026. The Board also approved the audited standalone and consolidated financial results for the same period with an unmodified auditor's opinion. Key subsidiaries contributed significantly, with three audited entities reporting a combined revenue of ₹8,968 million and a net profit of ₹736 million. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended final dividend of ₹5 per equity share of ₹10 each (50% payout rate)
Audited consolidated financial results for FY26 approved with an unmodified auditor opinion
Three audited subsidiaries reported total revenue of ₹8,968 million and net profit of ₹736 million
Total assets for the audited subsidiaries stood at ₹10,224 million as of March 31, 2026
Dividend to be paid within 30 days from the date of shareholder approval at the AGM
👀 What to Watch
Investors should look out for the upcoming record date announcement to qualify for the ₹5 dividend. The unmodified audit report and steady dividend payout suggest stable financial health for the company.
Strides Pharma Restructures Board; Elevates COO to Executive Director
Strides Pharma Science Limited has announced a significant leadership restructuring effective June 1, 2026, to professionalize management and strengthen its board. Venkata Seetharama Raju Pakalapati, an 18-year company veteran and current COO, has been elevated to Executive Director and Key Managerial Personnel (KMP). In a strategic move, Aditya Arun Kumar (son of the founder) will transition from an executive role to a Non-Executive Director. Additionally, Nandini Matiyani has been promoted to Group CHRO, and Ariff Khan has been nominated as Senior Management Personnel (SMP).
Key Highlights
Venkata Seetharama Raju Pakalapati (COO) elevated to Executive Director for a 3-year term starting June 1, 2026
Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to professionalize management
Nandini Matiyani, with 20+ years of experience, promoted to Group CHRO and Senior Management Personnel
Ariff Khan (EVP - Manufacturing Operations) nominated as Senior Management Personnel
Restructuring follows a comprehensive succession planning framework and internal talent promotion strategy
👀 What to Watch
Investors should view the transition toward professionalized management and internal leadership elevation as a positive sign of corporate governance. Monitor the company's operational efficiency under the newly elevated technical leadership.
Strides Pharma Recommends Final Dividend of Rs. 5 per Share for FY26
Strides Pharma Science Limited has recommended a final dividend of Rs. 5 per equity share (50% of face value) for the financial year ended March 31, 2026. The Board also approved the audited financial results for the quarter and full year, with auditors providing an unmodified opinion on the consolidated statements. Key subsidiary performance was notable, with three audited subsidiaries contributing Rs. 8,968 million in revenue and Rs. 736 million in net profit. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs. 5 per equity share of Rs. 10 face value (50% payout).
Audited consolidated financial results for FY26 approved with an unmodified auditor's opinion.
Three audited subsidiaries reported total revenue of Rs. 8,968 million and net profit of Rs. 736 million.
Total assets for the audited subsidiaries stood at Rs. 10,224 million as of March 31, 2026.
Dividend to be paid within 30 days from the date of shareholder approval at the ensuing AGM.
👀 What to Watch
Investors should monitor the announcement of the record date to ensure eligibility for the Rs. 5 per share dividend. The unmodified audit report and subsidiary profitability indicate a stable financial position for the company.
Strides Pharma FY26 Operational PAT Jumps 50% to ₹5,181m; Dividend of ₹5 Declared
Strides Pharma Science Limited reported a robust financial performance for FY26, with Operational PAT surging 50.3% YoY to ₹5,181m. Revenue grew by 6.4% to ₹48,587m, largely driven by a 21% growth in Ex-US markets which reached $254m. The company demonstrated strong financial discipline, improving its EBITDA margin to 19% and reducing its Net Debt/EBITDA ratio to 1.55x. A dividend of ₹5 per share has been recommended, reflecting management's confidence in sustainable growth.
Key Highlights
FY26 Operational PAT grew 50.3% YoY to ₹5,181m with Operational EPS rising to ₹56.2.
Ex-US markets revenue grew 21% YoY to $254m, offsetting a flat US market performance of $284m.
EBITDA margins expanded by 140bps YoY to 19.0% due to focus on high-margin products.
Net Debt/EBITDA improved to 1.55x from 1.90x, despite a ₹1,115m adverse currency impact.
Board recommended a dividend of ₹5 per share for the financial year ended March 31, 2026.
👀 What to Watch
Investors should take note of the significant margin expansion and successful debt reduction, which strengthen the balance sheet. The strong growth in non-US regulated markets provides a diversified revenue stream, making the stock attractive for long-term pharmaceutical sector exposure.
Strides Pharma FY26 Operational PAT Jumps 50% to ₹5,181m; Recommends ₹5 Dividend
Strides Pharma reported a robust performance for FY26, with Operational PAT growing 50.3% YoY to ₹5,181 million. The growth was primarily driven by Ex-US markets, which surged 21% YoY, while the US market remained stable with 2% growth. Profitability improved significantly as EBITDA margins expanded by 140 basis points to 19%, and the company successfully reduced its leverage, bringing the Net Debt to EBITDA ratio down to 1.55x from 1.9x. The Board has also recommended a dividend of ₹5 per share, reflecting confidence in the company's cash flow.
Key Highlights
Operational PAT grew 50.3% YoY to ₹5,181m with an Operational EPS of ₹56.2.
Ex-US market revenue showed strong momentum, growing 21% YoY to ₹22,404m.
EBITDA margins expanded to 19% (up 140bps) supported by a 310bps improvement in Gross Margins.
Net Debt to EBITDA ratio improved to 1.55x in FY26 from 1.9x in FY25.
Return on Capital Employed (RoCE) increased to 15.8% from 14.9% in the previous year.
👀 What to Watch
Investors should take note of the strong operational leverage and the significant growth in non-US markets which are diversifying the revenue base. The improving debt profile and margin expansion make this a positive outlook for long-term shareholders.
Strides Pharma Elevates COO to Board; Promoter Son Moves to Non-Executive Role
Strides Pharma Science Limited has announced a strategic management reshuffle effective June 1, 2026, aimed at professionalizing its leadership. Ramaraju PVS, an 18-year veteran and current COO, has been elevated to the Board as an Executive Director for a three-year term. Aditya Arun Kumar, son of the founder, will transition from an executive to a Non-Executive Director role to support the company's long-term strategic direction. Furthermore, Nandini Matiyani is promoted to Group CHRO, bringing over 20 years of HR experience to the Senior Management Personnel team.
Key Highlights
Ramaraju PVS (COO) elevated to Executive Director and KMP for a 3-year term starting June 1, 2026.
Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to further professionalize management.
Nandini Matiyani, with 20+ years of experience, promoted to Group CHRO and Senior Management Personnel.
The Board will consist of 9 directors, including 5 Independent Directors and 2 Executive Directors.
👀 What to Watch
The move to professionalize management by shifting promoter family members to non-executive roles and promoting long-term internal talent is a positive governance signal. Investors should view this as a sign of organizational maturity and stability.
Starteck Finance Recommends Rs 0.25 Dividend; Promoters Waive Payout Rights
Starteck Finance has recommended a final dividend of Rs 0.25 per equity share (2.5% of face value) for the financial year ended March 31, 2026. A significant highlight of this announcement is that the Promoter and Promoter Group have voluntarily waived their rights to receive this dividend. The company also approved its audited financial results for FY26, which received an unmodified (unqualified) opinion from the auditors. Additionally, the board has proposed the appointment of M/s. Bagaria & Co. LLP as the new statutory auditors for a five-year term.
Key Highlights
Recommended a final dividend of Rs 0.25 per equity share of Face Value Rs 10.
Promoter and Promoter Group have waived their rights to receive the dividend for FY26.
Statutory Auditors issued an unmodified (unqualified) opinion on the FY26 financial statements.
Proposed appointment of M/s. Bagaria & Co. LLP as Statutory Auditors for a 5-year term starting from the 41st AGM.
Re-appointed M/s Sandeep V. Chavan and Co. as Internal Auditors for the Financial Year 2026-27.
👀 What to Watch
The promoter dividend waiver is a positive signal for minority shareholders as it preserves cash for the company while rewarding public investors. Shareholders should monitor the upcoming AGM for the final approval of the dividend and auditor appointments.
Starteck Finance Recommends Re. 0.25 Dividend; Appoints New Statutory Auditors
Starteck Finance Limited approved its FY2026 audited financial results with an unmodified audit opinion from current auditors. The board recommended a final dividend of 2.5% (Re. 0.25 per share), though the promoter group has notably waived their right to receive this payout. Furthermore, M/s. Bagaria & Co. LLP has been appointed as the new statutory auditors for a five-year term, subject to shareholder approval at the upcoming AGM. The company also re-appointed its internal auditor for the 2026-27 financial year.
Key Highlights
Recommended final dividend of 2.5% (Re. 0.25 per share) for the financial year ended March 31, 2026.
Promoter and Promoter Group have waived their rights to receive the dividend payout.
Appointment of M/s. Bagaria & Co. LLP as Statutory Auditors for a 5-year term from the 41st AGM to the 46th AGM.
Current Statutory Auditors issued an unmodified (unqualified) opinion on both Standalone and Consolidated FY26 financials.
Re-appointment of M/s Sandeep V. Chavan and Co. as Internal Auditor for the Financial Year 2026-27.
👀 What to Watch
The promoter's waiver of dividends is a positive signal of commitment to the company's cash reserves. Investors should monitor the transition to the new statutory auditor to ensure continued reporting transparency.
Starteck Finance Reports FY26 Results, Recommends Re 0.25 Dividend; Promoters Waive Payout
Starteck Finance has approved its audited financial results for the year ended March 31, 2026, receiving an unqualified audit opinion from its statutory auditors. The Board recommended a final dividend of 2.5% (Re. 0.25 per share), which is notably enhanced for minority shareholders as the Promoter Group has waived their dividend rights. Additionally, the company has proposed the appointment of Bagaria & Co. LLP as the new statutory auditors for a five-year tenure. The consolidated performance includes contributions from its wholly-owned subsidiaries, Chitta Finlease and Bhuwalka Steel Industries.
Key Highlights
Recommended final dividend of Re. 0.25 per share (2.5% of face value) for FY 2025-26.
Promoter and Promoter Group have voluntarily waived their rights to receive the dividend.
Statutory Auditors issued an unmodified (unqualified) opinion on both standalone and consolidated financial statements.
M/s. Bagaria & Co. LLP appointed as Statutory Auditors for a 5-year term starting from the 41st AGM.
Consolidated results include wholly-owned subsidiaries Chitta Finlease and Bhuwalka Steel Industries.
👀 What to Watch
The promoter dividend waiver is a strong positive signal regarding corporate governance and capital allocation favoring minority shareholders. Investors should monitor the company's asset quality and loan book growth trends in the detailed financial report.
Blue Star Q4 FY26 Revenue Hits Record ₹4,072 Cr; Recommends ₹8.5 Dividend
Blue Star reported its highest-ever quarterly revenue of ₹4,072 crore in Q4 FY26, marking a 1.3% YoY growth despite a challenging year. While annual net profit for FY26 declined by 4.3% to ₹527.3 crore due to supply chain headwinds and a weak initial summer, the company's order book remains robust at ₹6,923 crore. The Board has recommended a dividend of ₹8.5 per share. Management expressed cautious optimism for FY27, citing a strong start to the summer season in April 2026.
Key Highlights
Q4 FY26 consolidated revenue grew 1.3% YoY to ₹4,072 crore, while EBITDA margins improved to 8%.
Full-year FY26 revenue increased 3.6% to ₹12,402 crore, though net profit fell to ₹527.3 crore.
The carried forward order book grew by 10.5% YoY to reach ₹6,923 crore as of March 31, 2026.
Unitary Products (Segment 2) margins improved to 10.4% in Q4 FY26 from 8.4% in the previous year.
Board recommended a dividend of ₹8.5 per share for the financial year ended March 31, 2026.
👀 What to Watch
Investors should focus on the recovery in the room air conditioner segment and the strong order book in electromechanical projects. While Q4 showed margin improvement, watch for the impact of rising input costs and geopolitical supply chain disruptions in FY27.
Sanstar Commissions Dhule Capacity Expansion; Total Capacity Reaches 2,350 TPD
Sanstar Limited has successfully commissioned its expanded native starch manufacturing capacity at the Dhule facility, doubling its total installed capacity from 1,100 TPD to 2,350 TPD. The project fully utilized Rs. 1,816 million of IPO proceeds and exceeded the original expansion target of 1,000 MTPD by achieving 1,250 MTPD. While the native starch phase is now operational, the high-value derivatives facility is expected to be commissioned in FY2026-27. This expansion positions Sanstar as the second-largest maize-based specialty products manufacturer in India.
Key Highlights
Total installed capacity increased significantly from 1,100 TPD to 2,350 TPD
Fully utilized Rs. 1,816 million of IPO proceeds for the Dhule facility expansion
Achieved 1,250 MTPD capacity addition, exceeding the initial IPO plan of 1,000 MTPD
Derivatives facility phase is on track for commissioning within FY2026-27
Strategic location in Dhule offers logistical advantages for both domestic sourcing and exports
👀 What to Watch
Investors should monitor the capacity utilization rates and revenue growth in the coming quarters as the new capacity ramps up. The upcoming derivatives facility in FY27 will be a critical driver for margin expansion through value-added products.
Blue Star Q4 Net Profit Rises 17% to ₹227 Cr; FY26 Dividend Recommended at ₹8.5 Per Share
Blue Star reported a modest 1.3% revenue growth in Q4FY26 to ₹4072.06 cr, though net profit surged 17.1% to ₹227.18 cr driven by improved EBITDA margins of 8.0%. For the full year FY26, the company faced headwinds with net profit declining 10.8% to ₹527.33 cr, primarily due to a challenging environment and exceptional items related to labor codes. The order book remains healthy at ₹6923 cr, up 10.5% YoY, providing revenue visibility for the upcoming year. The Board recommended a dividend of ₹8.5 per share, slightly lower than the previous year's ₹9.
Key Highlights
Q4FY26 Net Profit grew 17.1% YoY to ₹227.18 cr, while Revenue saw a marginal 1.3% increase to ₹4072.06 cr.
Full-year FY26 Net Profit declined by 10.8% to ₹527.33 cr despite a 3.6% growth in total revenue to ₹12401.99 cr.
Carried-forward order book grew 10.5% to ₹6923 cr as of March 31, 2026, with strong Q4 order inflows in the Projects segment.
Unitary Products (AC segment) margins improved significantly to 10.4% in Q4 from 8.4% YoY due to cost rationalization.
Recommended dividend of ₹8.5 per share for FY26, representing a slight decrease from ₹9.0 in FY25.
👀 What to Watch
Investors should monitor the sustainability of the margin expansion in the Unitary Products segment and the execution of the ₹6,923 cr order book. While full-year profits were down, the strong Q4 performance and pickup in summer demand in April 2026 suggest a potential recovery in FY27.
Blue Star Q4 FY26 EBITDA Grows 16.8% to ₹326 Cr; Revenue Hits ₹4,072 Cr
Blue Star reported a steady Q4 FY26 with revenue growing marginally to ₹4,072 crore, while EBITDA saw a significant 16.8% increase to ₹326 crore. The Unitary Products segment (Room ACs) showed margin improvement to 10.4% despite stagnant growth in deep freezers. However, full-year EPS declined to ₹25.65 from ₹28.76, impacted by a ₹38 crore exceptional one-time charge related to new labor codes. The company maintains a healthy balance sheet with a net cash position of ₹175 crore and a low debt-equity ratio of 0.18.
Key Highlights
Q4 FY26 EBITDA increased to ₹326 crore from ₹279 crore in the previous year, with margins improving to 8.0%.
Unitary Products EBIT margins improved significantly to 10.4% in Q4 FY26 from 8.4% YoY.
Electro-Mechanical Projects (EMP) order bookings grew by 35% driven by demand from Data Centers and Factories.
Full-year FY26 revenue reached ₹12,402 crore, though EPS fell to ₹25.65 due to a ₹38 crore exceptional gratuity impact.
Net cash position decreased to ₹175 crore from ₹640 crore YoY, while the debt-equity ratio remains low at 0.18.
👀 What to Watch
Investors should monitor the margin recovery in the EMP segment and the scalability of the US/Europe expansion. While Q4 was strong, the full-year earnings dip and lower net cash suggest a need for a cautious outlook on immediate valuation upside.
Blue Star Q4 Net Profit Rises 17% to Rs 227 Cr; FY26 Dividend Declared at Rs 8.5/Share
Blue Star reported a record quarterly revenue of Rs 4072.06 crore in Q4FY26, up 1.3% YoY, driven by a late surge in Room Air Conditioner demand. While Q4 net profit grew 17% to Rs 227.18 crore, the full-year FY26 net profit saw a 4.3% decline to Rs 527.33 crore due to challenging conditions earlier in the year. The company's order book remains robust at Rs 6923 crore, representing a 10.5% YoY growth. Management has recommended a dividend of Rs 8.5 per share and remains cautiously optimistic for FY27 as summer demand picked up in April 2026.
Key Highlights
Q4FY26 EBITDA margins improved to 8.0% from 7.0% YoY, driven by cost rationalization and prudent pricing.
Carried-forward order book grew 10.5% YoY to reach Rs 6923 crore as of March 31, 2026.
Segment II (Unitary Products) margins rose to 10.4% in Q4FY26 compared to 8.4% in the previous year.
Full-year FY26 revenue grew 3.6% to Rs 12401.99 crore, though PBT before exceptional items fell 3.9%.
Board recommended a dividend of Rs 8.5 per share for FY26, down from Rs 9 per share in FY25.
👀 What to Watch
Investors should focus on the strong Q4 margin recovery and the 10.5% growth in the order book as indicators of future performance. The reported pickup in secondary sales in April 2026 suggests a potentially strong start to FY27, making the next quarter's volume growth a key metric to watch.
Blue Star Q4 FY26 Revenue Grows 12% to ₹2,790 Cr; EBITDA Margins Expand to 8%
Blue Star reported a steady Q4 FY26 with revenue growing 12% YoY to ₹2,790 crore and EBITDA margins improving to 8% from 7% in the previous year. While the full-year revenue grew modestly by 3.6% to ₹12,402 crore, the company faced a one-time exceptional hit of ₹38 crore due to new labor code provisions affecting full-year EPS. Segment 1 (EMP) saw strong order booking growth of 35% in Q4, while Segment 2 (Unitary Products) margins improved significantly to 10.4%. The company maintains a healthy balance sheet with a low debt-equity ratio of 0.18.
Key Highlights
Q4 FY26 Revenue increased 12% YoY to ₹2,790 crore, with EBITDA rising 16.8% to ₹326 crore.
Unitary Products (Room ACs) segment EBIT margins improved to 10.4% in Q4 from 8.4% YoY.
Electro-Mechanical Projects (EMP) saw a robust 35% growth in order bookings during the quarter.
Full-year FY26 results were impacted by a ₹38 crore exceptional charge for gratuity and leave encashment.
Net cash position decreased to ₹175 crore from ₹640 crore, while Debt-Equity ratio remains low at 0.18.
👀 What to Watch
Investors should focus on the strong margin recovery in the Unitary Products segment and the robust order pipeline in EMP. The stock remains a solid play on India's cooling and infrastructure growth, though full-year growth was slightly muted due to one-off costs.
Blue Star Recommends ₹8.5 Dividend; Approves Audited FY26 Financial Results
Blue Star's Board has recommended a final dividend of ₹8.5 per equity share (425% of face value) for the financial year ended March 31, 2026. The company approved its audited financial results for FY26, which received an unmodified opinion from statutory auditors Deloitte Haskins & Sells LLP. The record date for the dividend is set for July 17, 2026, with the payout expected after the Annual General Meeting on August 6, 2026. This announcement signals a steady return to shareholders alongside the completion of the fiscal year.
Key Highlights
Recommended a final dividend of ₹8.5 per equity share of ₹2 face value for FY26.
Fixed July 17, 2026, as the Record Date for determining dividend eligibility.
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.
Statutory auditors issued an unmodified audit report, confirming financial transparency.
The 78th Annual General Meeting (AGM) is scheduled for August 6, 2026.
👀 What to Watch
Investors seeking dividend income should ensure they hold shares by the record date of July 17, 2026. The clean audit report and substantial dividend payout suggest stable financial health for the company.
Blue Star Recommends ₹8.5 Final Dividend and Approves FY26 Audited Results
Blue Star Limited's Board has recommended a final dividend of ₹8.5 per equity share for the financial year ended March 31, 2026. The company also approved its audited financial results for FY26, which received a clean, unmodified report from statutory auditors Deloitte Haskins & Sells LLP. The record date for dividend eligibility is fixed as July 17, 2026, with the payout scheduled after the Annual General Meeting on August 6, 2026. This announcement confirms the company's year-end financial performance and shareholder reward policy.
Key Highlights
Recommended a final dividend of ₹8.5 per equity share of ₹2 face value for FY26.
Record date for the final dividend is set for July 17, 2026.
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.
Statutory auditors issued an unmodified audit report on the financial results.
The 78th Annual General Meeting (AGM) is scheduled for August 6, 2026.
👀 What to Watch
Investors seeking dividend income should ensure they hold shares before the record date of July 17, 2026. The unmodified audit report is a positive sign of financial transparency and reporting integrity.
